A changing landscape in castration-resistant prostate cancer treatment.
Ontology highlight
ABSTRACT: Prostate cancer (PC) is the leading cause of cancer and the second leading cause of cancer-death among men in the Western world. About 10-20% of men with PC present with metastatic disease at diagnosis, while 20-30% of patients diagnosed with localized disease will eventually develop metastases. Although most respond to initial androgen-deprivation therapy (ADT), progression to castration-resistant PC (CRPC) is universal. In 2004 the docetaxel/prednisone regimen was approved for the management of patients with metastatic CRPC, becoming the standard first-line therapy. Recent advances have now led to an unprecedented number of new drug approvals within the past years, providing many new treatment options for patients with metastatic CRPC. Four new drugs have received U.S. Food and Drug Admi
SUBMITTER: Felici A
PROVIDER: S-EPMC3399094 | biostudies-literature | 2012
REPOSITORIES: biostudies-literature
ACCESS DATA